Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 31;15(1):101-111.
doi: 10.21037/jtd-22-1523. Epub 2023 Jan 16.

High expression of FGFR3 predicts a better prognosis for patients with non-small cell lung cancer in a Chinese population

Yun-En Lin #  1 , Hui-Dong Long #  2 , Cheng-Cong Chen #  3 , Guan-Cheng Liu  4 , Feng Li  3 , Yun-Hong Tian  3 , Lu Dai  5
Affiliations

High expression of FGFR3 predicts a better prognosis for patients with non-small cell lung cancer in a Chinese population

Yun-En Lin et al. J Thorac Dis. .

Abstract

Background: This study sought to examine the expression and mutation status of fibroblast growth factor receptor 3 (FGFR3) in non-small cell lung cancer (NSCLC) tissues and explore the prognostic potential of FGFR3 in NSCLC.

Methods: Immunohistochemistry (IHC) was used to evaluate the FGFR3 protein expression of 116 NSCLC tissues. Sanger sequencing was used to examine the mutation status of exons 7, 10, and 15 in FGFR3. A Kaplan‑Meier survival analysis was conducted to evaluate the association between the expression level of FGFR3 and the overall survival (OS) and disease-free survival (DFS) of NSCLC patients. Univariate and multivariate Cox analyses were conducted to examine the association between the risk score and clinical features.

Results: FGFR3 was immunoreactive in 26 of the 86 NSCLC cases. Further, FGFR3 was positively expressed in 84.6% of the lung adenocarcinoma (AC) cases and 15.4% of the lung squamous cell carcinoma (SCC) cases. FGFR3 mutations were detected in 2 NSCLC patients (2/72, 2.8%), who both harbored the T450M mutation, a novel mutation in exon 10 of FGFR3. In NSCLC, a high expression of FGFR3 was positively correlated with gender, smoking, histology type, T stage, and the epidermal growth factor receptor (EGFR) mutation (P<0.05). FGFR3 expression was also correlated with better OS and DFS. The multivariate analysis revealed that FGFR3 served as an independent prognostic factor (P=0.024) for the OS of NSCLC patients.

Conclusions: This study showed that FGFR3 was highly expressed in NSCLC tissues, and the frequency rate for the FGFR3 mutation at T450 M in NSCLC tissues was low. The survival analysis suggested that FGFR3 may be a useful prognostic biomarker in NSCLC.

Keywords: Fibroblast growth factor receptor 3 (FGFR3); immunohistochemistry (IHC); mutation; non-small cell lung cancer (NSCLC); prognosis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-1523/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
IHC staining of FGFR3 expression in lung tissues. (A) Negative staining of FGFR3 in normal lung tissues (40× magnification). (B) Low expression of FGFR3 in NSCLC tissues (40× magnification). (C) High expression of FGFR3 in NSCLC tissues (40× magnification). (D) Negative staining of FGFR3 in normal lung tissues (100× magnification). (E) Low expression of FGFR3 in NSCLC tissues (100× magnification). (F) High expression of FGFR3 in NSCLC tissues (100× magnification). IHC, immunohistochemistry; FGFR3, fibroblast growth factor receptor 3; NSCLC, non-small cell lung cancer.
Figure 2
Figure 2
Sanger sequencing of FGFR3 gene. (A) The wild-type FGFR3 profile, and (B) a T450M-mutated tumor, characterized by a C > T base substitution in codon 450. FGFR3, fibroblast growth factor receptor 3.
Figure 3
Figure 3
Kaplan-Meier survival analysis of FGFR3 expression in NSCLC patients. Association between FGFR3 expression and the (A) OS and (B) DFS of the NSCLC patients. FGFR3, fibroblast growth factor receptor 3; NSCLC, non-small lung cell cancer; OS, overall survival; DFS, disease-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Extracellular Matrix Sulfation in the Tumor Microenvironment Stimulates Cancer Stemness and Invasiveness.
    Kuşoğlu A, Örnek D, Dansık A, Uzun C, Nur Özkan S, Sarıca S, Yangın K, Özdinç Ş, Sorhun DT, Solcan N, Doğanalp EC, Arlov Ø, Cunningham K, Karaoğlu IC, Kizilel S, Solaroğlu I, Bulutay P, Fırat P, Erus S, Tanju S, Dilege Ş, Vunjak-Novakovic G, Tuncbag N, Öztürk E. Kuşoğlu A, et al. Adv Sci (Weinh). 2024 Sep;11(36):e2309966. doi: 10.1002/advs.202309966. Epub 2024 Jul 31. Adv Sci (Weinh). 2024. PMID: 39083319 Free PMC article.

References

    1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33. 10.3322/caac.21708 - DOI - PubMed
    1. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018;553:446-54. 10.1038/nature25183 - DOI - PubMed
    1. Jonna S, Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discov Med 2019;27:167-70. - PubMed
    1. Chen P, Liu Y, Wen Y, et al. Non-small cell lung cancer in China. Cancer Commun (Lond) 2022. - PMC - PubMed
    1. Yu P, He X, Lu F, et al. Research progress regarding long-chain non-coding RNA in lung cancer: a narrative review. J Thorac Dis 2022;14:3016-29. 10.21037/jtd-22-897 - DOI - PMC - PubMed